Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Near-infrared dual bioluminescence imaging in mouse models of cancer using infraluciferin.

Stowe CL, Burley TA, Allan H, Vinci M, Kramer-Marek G, Ciobota DM, Parkinson GN, Southworth TL, Agliardi G, Hotblack A, Lythgoe MF, Branchini BR, Kalber TL, Anderson JC, Pule MA.

Elife. 2019 Oct 15;8. pii: e45801. doi: 10.7554/eLife.45801. [Epub ahead of print]

2.

Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.

Burley TA, Da Pieve C, Martins CD, Ciobota DM, Allott L, Oyen WJG, Harrington KJ, Smith G, Kramer-Marek G.

J Nucl Med. 2019 Mar;60(3):353-361. doi: 10.2967/jnumed.118.216069. Epub 2018 Sep 13.

3.

Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma.

Baker LCJ, Sikka A, Price JM, Boult JKR, Lepicard EY, Box G, Jamin Y, Spinks TJ, Kramer-Marek G, Leach MO, Eccles SA, Box C, Robinson SP.

Front Oncol. 2018 Jul 23;8:271. doi: 10.3389/fonc.2018.00271. eCollection 2018.

4.

Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure.

King A, Doepner A, Turton D, Ciobota DM, Da Pieve C, Wong Te Fong AC, Kramer-Marek G, Chung YL, Smith G.

Org Biomol Chem. 2018 Apr 25;16(16):2986-2996. doi: 10.1039/c8ob00432c.

5.

HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.

Martins CD, Da Pieve C, Burley TA, Smith R, Ciobota DM, Allott L, Harrington KJ, Oyen WJG, Smith G, Kramer-Marek G.

Clin Cancer Res. 2018 Apr 15;24(8):1853-1865. doi: 10.1158/1078-0432.CCR-17-2754. Epub 2018 Feb 6.

6.

Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.

Burley TA, Mączyńska J, Shah A, Szopa W, Harrington KJ, Boult JKR, Mrozek-Wilczkiewicz A, Vinci M, Bamber JC, Kaspera W, Kramer-Marek G.

Int J Cancer. 2018 Jun 1;142(11):2363-2374. doi: 10.1002/ijc.31246. Epub 2018 Jan 19.

7.

Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges.

Martins CD, Kramer-Marek G, Oyen WJG.

Expert Opin Drug Deliv. 2018 Feb;15(2):185-196. doi: 10.1080/17425247.2018.1378180. Epub 2017 Sep 12. Review.

PMID:
28893110
8.

Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89.

Allott L, Da Pieve C, Meyers J, Spinks T, Ciobota DM, Kramer-Marek G, Smith G.

Chem Commun (Camb). 2017 Jul 27;53(61):8529-8532. doi: 10.1039/c7cc03572a.

9.

Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.

Szopa W, Burley TA, Kramer-Marek G, Kaspera W.

Biomed Res Int. 2017;2017:8013575. doi: 10.1155/2017/8013575. Epub 2017 Feb 20. Review.

10.

Pre-clinical quantitative imaging and mouse-specific dosimetry for 111In-labelled radiotracers.

Denis-Bacelar AM, Cronin SE, Da Pieve C, Paul RL, Eccles SA, Spinks TJ, Box C, Hall A, Sosabowski JK, Kramer-Marek G, Flux GD.

EJNMMI Res. 2016 Dec;6(1):85. Epub 2016 Nov 25.

11.

Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors.

Da Pieve C, Allott L, Martins CD, Vardon A, Ciobota DM, Kramer-Marek G, Smith G.

Bioconjug Chem. 2016 Aug 17;27(8):1839-49. doi: 10.1021/acs.bioconjchem.6b00259. Epub 2016 Jul 19.

12.

Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside.

Kramer-Marek G, Oyen WJ.

J Nucl Med. 2016 Jul;57(7):996-1001. doi: 10.2967/jnumed.115.169540. Epub 2016 May 12. Review. No abstract available.

13.

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roulstone V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoo V, Harrington KJ.

Gene Ther. 2016 Apr;23(4):357-68. doi: 10.1038/gt.2016.5. Epub 2016 Jan 27.

14.

Computer-aided pulmonary image analysis in small animal models.

Xu Z, Bagci U, Mansoor A, Kramer-Marek G, Luna B, Kubler A, Dey B, Foster B, Papadakis GZ, Camp JV, Jonsson CB, Bishai WR, Jain S, Udupa JK, Mollura DJ.

Med Phys. 2015 Jul;42(7):3896-910. doi: 10.1118/1.4921618.

15.

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL, Bridges E, Capala J, Ioannis R, Harris AL, Kong A.

Oncotarget. 2014 Aug 15;5(15):5934-49.

16.

Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies.

Adesina SK, Holly A, Kramer-Marek G, Capala J, Akala EO.

J Pharm Sci. 2014 Aug;103(8):2546-55. doi: 10.1002/jps.24061. Epub 2014 Jun 24.

17.

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A.

Oncotarget. 2014 Aug 30;5(16):6633-46.

18.

Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.

Kramer-Marek G, Gore J, Korc M.

Cancer Lett. 2013 Dec 1;341(2):132-8. doi: 10.1016/j.canlet.2013.08.008. Epub 2013 Aug 11. Review.

19.

Automated computer quantification of breast cancer in small-animal models using PET-guided MR image co-segmentation.

Bagci U, Kramer-Marek G, Mollura DJ.

EJNMMI Res. 2013 Jul 5;3(1):49. doi: 10.1186/2191-219X-3-49.

20.

Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.

Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.

J Nucl Med. 2012 Oct;53(10):1592-600. doi: 10.2967/jnumed.111.102293. Epub 2012 Aug 23.

21.

Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy.

Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke PL, Kobayashi H.

BMC Cancer. 2012 Aug 8;12:345. doi: 10.1186/1471-2407-12-345.

22.

Recent advances in optical cancer imaging of EGF receptors.

Kramer-Marek G, Longmire MR, Choyke PL, Kobayashi H.

Curr Med Chem. 2012;19(28):4759-66. Review.

23.

PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.

Kramer-Marek G, Bernardo M, Kiesewetter DO, Bagci U, Kuban M, Aras O, Zielinski R, Seidel J, Choyke P, Capala J.

J Nucl Med. 2012 Jun;53(6):939-46. doi: 10.2967/jnumed.111.100354. Epub 2012 May 11. Erratum in: J Nucl Med. 2012 Jul;53(7):1169. Omer, Aras [corrected to Aras, Omer].

24.

Can PET imaging facilitate optimization of cancer therapies?

Kramer-Marek G, Capala J.

Curr Pharm Des. 2012;18(18):2657-69. Review.

PMID:
22512443
25.

The role of nuclear medicine in modern therapy of cancer.

Kramer-Marek G, Capala J.

Tumour Biol. 2012 Jun;33(3):629-40. doi: 10.1007/s13277-012-0373-8. Epub 2012 Mar 24. Review.

PMID:
22446937
26.

Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model.

Kramer-Marek G, Gijsen M, Kiesewetter DO, Bennett R, Roxanis I, Zielinski R, Kong A, Capala J.

J Nucl Med. 2012 Apr;53(4):629-37. doi: 10.2967/jnumed.111.096685. Epub 2012 Mar 12.

27.

Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells.

Dahl M, Bouchelouche P, Kramer-Marek G, Capala J, Nordling J, Bouchelouche K.

Mol Biol Rep. 2011 Oct;38(7):4237-43. doi: 10.1007/s11033-010-0442-2. Epub 2011 Jul 14.

28.

68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.

Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J.

Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1967-76. doi: 10.1007/s00259-011-1810-4. Epub 2011 Apr 20.

29.

HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.

Lyakhov I, Zielinski R, Kuban M, Kramer-Marek G, Fisher R, Chertov O, Bindu L, Capala J.

Chembiochem. 2010 Feb 15;11(3):345-50. doi: 10.1002/cbic.200900532.

30.

Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.

Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N, Stephen A, Fisher R, Blumenthal R, Capala J.

J Immunother. 2009 Oct;32(8):817-25. doi: 10.1097/CJI.0b013e3181ad4d5d.

31.

Radiolabeling of HER2 specific Affibody(R) molecule with F-18.

Kiesewetter DO, Krämer-Marek G, Ma Y, Capala J.

J Fluor Chem. 2008 Sep;129(9):799-805.

32.

Comparison of photodynamic efficacy of tetraarylporphyrin pegylated or encapsulated in liposomes: in vitro studies.

Nawalany K, Rusin A, Kepczyński M, Mikhailov A, Kramer-Marek G, Snietura M, Połtowicz J, Krawczyk Z, Nowakowska M.

J Photochem Photobiol B. 2009 Oct 6;97(1):8-17. doi: 10.1016/j.jphotobiol.2009.07.005. Epub 2009 Jul 12.

PMID:
19665390
33.

Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.

Kramer-Marek G, Kiesewetter DO, Capala J.

J Nucl Med. 2009 Jul;50(7):1131-9. doi: 10.2967/jnumed.108.057695. Epub 2009 Jun 12.

34.

Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parameters.

Morgan NY, Kramer-Marek G, Smith PD, Camphausen K, Capala J.

Radiat Res. 2009 Feb;171(2):236-44. doi: 10.1667/RR1470.1. Review.

35.

HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents.

Puri A, Kramer-Marek G, Campbell-Massa R, Yavlovich A, Tele SC, Lee SB, Clogston JD, Patri AK, Blumenthal R, Capala J.

J Liposome Res. 2008;18(4):293-307. doi: 10.1080/08982100802457377 .

36.

Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.

Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, Gandjbakhche A, Capala J.

Clin Cancer Res. 2008 Jun 15;14(12):3840-9. doi: 10.1158/1078-0432.CCR-07-4076.

37.

[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.

Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J.

Eur J Nucl Med Mol Imaging. 2008 May;35(5):1008-18. Epub 2007 Dec 22.

38.

Spectroscopic properties and photodynamic effects of new lipophilic porphyrin derivatives: efficacy, localisation and cell death pathways.

Kramer-Marek G, Serpa C, Szurko A, Widel M, Sochanik A, Snietura M, Kus P, Nunes RM, Arnaut LG, Ratuszna A.

J Photochem Photobiol B. 2006 Jul 3;84(1):1-14. Epub 2006 Feb 21. Erratum in: J Photochem Photobiol B. 2006 Dec 1;85(3):228.

PMID:
16495073
39.

Photodynamic effects of two water soluble porphyrins evaluated on human malignant melanoma cells in vitro.

Szurko A, Krämer-Marek G, Wideł M, Ratuszna A, Habdas J, Kuś P.

Acta Biochim Pol. 2003;50(4):1165-74.

Supplemental Content

Loading ...
Support Center